Syros Pharmaceuticals
620 Memorial Drive
Cambridge
MA
02139
United States
153 articles about Syros Pharmaceuticals
-
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
5/25/2023
Syros Pharmaceuticals announced new clinical data from the Phase 1/1b clinical trial evaluating SY-5609, its highly selective and potent inhibitor of CDK7, in patients with relapsed/refractory pancreatic ductal adenocarcinoma, HR+ breast cancer and other solid tumors.
-
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
5/10/2023
Syros Pharmaceuticals today reported financial results for the quarter ended March 31, 2023 and provided a corporate update.
-
Syros to Present at JMP Securities 2023 Life Sciences Conference
5/9/2023
Syros Pharmaceuticals announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference.
-
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
5/3/2023
Syros Pharmaceuticals today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its first quarter 2023 financial results and provide a corporate update.
-
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/2/2023
Syros Pharmaceuticals today announced the grant of restricted stock unit (RSU) awards for an aggregate of 17,800 shares of Syros common stock to two newly hired employees in connection with commencing employment with Syros.
-
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
3/2/2023
Syros Pharmaceuticals today reported financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.
-
Syros to Participate in Upcoming Investor Conferences in March - February 28, 2023
2/28/2023
Syros Pharmaceuticals today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming investor conferences in March.
-
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
2/23/2023
Syros Pharmaceuticals today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.
-
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 09, 2023
2/9/2023
Syros Pharmaceuticals announced the grant of restricted stock unit awards for an aggregate of 12,400 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros.
-
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
1/26/2023
Syros Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome (HR-MDS).
-
Syros Announces Clinical Updates and 2023 Strategic Priorities
1/9/2023
Syros Pharmaceuticals today provided an update on its clinical development programs and outlined its strategic priorities for 2023.
-
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 23, 2022
12/23/2022
Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 14,200 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros.
-
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS
12/12/2022
Syros Pharmaceuticals today announced a peer-reviewed publication of results from its completed biomarker-directed Phase 2 trial of tamibarotene in combination with azacitidine in newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for standard intensive chemotherapy.
-
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
12/10/2022
Syros Pharmaceuticals announced data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective retinoic acid receptor alpha agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia and RARA gene overexpression.
-
Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10
12/5/2022
Syros Pharmaceuticals today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML).
-
Syros to Participate at Piper Sandler 34th Annual Healthcare Conference
11/22/2022
Syros Pharmaceuticals today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference.
-
Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
11/14/2022
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2022 and provided a corporate update.
-
Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
11/7/2022
Syros Pharmaceuticals today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, November 14, 2022 to report its third quarter 2022 financial results and provide a corporate update.
-
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 04, 2022
11/4/2022
Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 22,610 shares of Syros common stock to three newly hired employees in connection with their commencement of employment with Syros.
-
Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
11/3/2022
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, LA.